Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

Olivier Brouckaert, Saskia Pintens, Vanya Van Belle, Sabine Van Huffel, Edward Camerlynck, Frédéric Amant, Karin Leunen, An Smeets, Patrick Berteloot, Erik Van Limbergen, Julie Decock, Wouter R. Hendrickx, Caroline Weltens, Walter Van Den Bogaert, Isabelle Vanden Bempt, Maria Drijkoningen, Robert Paridaens, Hans Wildiers, Ignace Vergote, Marie Rose Christiaens & 1 others Patrick Neven

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.

Original languageEnglish
Pages (from-to)349-358
Number of pages10
JournalBreast Cancer Research and Treatment
Volume115
Issue number2
DOIs
Publication statusPublished - 1 May 2009
Externally publishedYes

Fingerprint

Hormones
Breast Neoplasms
Staining and Labeling
Steroid Receptors
Neoplasm Genes
Fluorescence In Situ Hybridization
Transcriptome
Cluster Analysis
Therapeutics
Complementary DNA
Joints
Phenotype
Recurrence
Membranes
Survival
Genes

Keywords

  • Breast cancer
  • Disease free interval
  • Disease free survival
  • Estrogen receptor
  • HER-2
  • Progesterone receptor
  • Steroid receptors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brouckaert, O., Pintens, S., Van Belle, V., Van Huffel, S., Camerlynck, E., Amant, F., ... Neven, P. (2009). Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment, 115(2), 349-358. https://doi.org/10.1007/s10549-008-0110-6

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. / Brouckaert, Olivier; Pintens, Saskia; Van Belle, Vanya; Van Huffel, Sabine; Camerlynck, Edward; Amant, Frédéric; Leunen, Karin; Smeets, An; Berteloot, Patrick; Van Limbergen, Erik; Decock, Julie; Hendrickx, Wouter R.; Weltens, Caroline; Van Den Bogaert, Walter; Vanden Bempt, Isabelle; Drijkoningen, Maria; Paridaens, Robert; Wildiers, Hans; Vergote, Ignace; Christiaens, Marie Rose; Neven, Patrick.

In: Breast Cancer Research and Treatment, Vol. 115, No. 2, 01.05.2009, p. 349-358.

Research output: Contribution to journalArticle

Brouckaert, O, Pintens, S, Van Belle, V, Van Huffel, S, Camerlynck, E, Amant, F, Leunen, K, Smeets, A, Berteloot, P, Van Limbergen, E, Decock, J, Hendrickx, WR, Weltens, C, Van Den Bogaert, W, Vanden Bempt, I, Drijkoningen, M, Paridaens, R, Wildiers, H, Vergote, I, Christiaens, MR & Neven, P 2009, 'Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors', Breast Cancer Research and Treatment, vol. 115, no. 2, pp. 349-358. https://doi.org/10.1007/s10549-008-0110-6
Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F et al. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment. 2009 May 1;115(2):349-358. https://doi.org/10.1007/s10549-008-0110-6
Brouckaert, Olivier ; Pintens, Saskia ; Van Belle, Vanya ; Van Huffel, Sabine ; Camerlynck, Edward ; Amant, Frédéric ; Leunen, Karin ; Smeets, An ; Berteloot, Patrick ; Van Limbergen, Erik ; Decock, Julie ; Hendrickx, Wouter R. ; Weltens, Caroline ; Van Den Bogaert, Walter ; Vanden Bempt, Isabelle ; Drijkoningen, Maria ; Paridaens, Robert ; Wildiers, Hans ; Vergote, Ignace ; Christiaens, Marie Rose ; Neven, Patrick. / Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. In: Breast Cancer Research and Treatment. 2009 ; Vol. 115, No. 2. pp. 349-358.
@article{037612ce5aa54336a01cb67c002e32ce,
title = "Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors",
abstract = "Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91{\%}; 94{\%} for PPN, 89{\%} for PNN, 86{\%} for NNN, 81{\%} for PPP, 80{\%} for PNP, and 76{\%} for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.",
keywords = "Breast cancer, Disease free interval, Disease free survival, Estrogen receptor, HER-2, Progesterone receptor, Steroid receptors",
author = "Olivier Brouckaert and Saskia Pintens and {Van Belle}, Vanya and {Van Huffel}, Sabine and Edward Camerlynck and Fr{\'e}d{\'e}ric Amant and Karin Leunen and An Smeets and Patrick Berteloot and {Van Limbergen}, Erik and Julie Decock and Hendrickx, {Wouter R.} and Caroline Weltens and {Van Den Bogaert}, Walter and {Vanden Bempt}, Isabelle and Maria Drijkoningen and Robert Paridaens and Hans Wildiers and Ignace Vergote and Christiaens, {Marie Rose} and Patrick Neven",
year = "2009",
month = "5",
day = "1",
doi = "10.1007/s10549-008-0110-6",
language = "English",
volume = "115",
pages = "349--358",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

AU - Brouckaert, Olivier

AU - Pintens, Saskia

AU - Van Belle, Vanya

AU - Van Huffel, Sabine

AU - Camerlynck, Edward

AU - Amant, Frédéric

AU - Leunen, Karin

AU - Smeets, An

AU - Berteloot, Patrick

AU - Van Limbergen, Erik

AU - Decock, Julie

AU - Hendrickx, Wouter R.

AU - Weltens, Caroline

AU - Van Den Bogaert, Walter

AU - Vanden Bempt, Isabelle

AU - Drijkoningen, Maria

AU - Paridaens, Robert

AU - Wildiers, Hans

AU - Vergote, Ignace

AU - Christiaens, Marie Rose

AU - Neven, Patrick

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.

AB - Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.

KW - Breast cancer

KW - Disease free interval

KW - Disease free survival

KW - Estrogen receptor

KW - HER-2

KW - Progesterone receptor

KW - Steroid receptors

UR - http://www.scopus.com/inward/record.url?scp=67349199171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349199171&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0110-6

DO - 10.1007/s10549-008-0110-6

M3 - Article

VL - 115

SP - 349

EP - 358

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -